SMAD5 and central nervous system cancer: LN18 glioma cells were pretreated with control (siCL), Smad1 (siSmad1)-, or Smad5 (siSmad5)-specific siRNAs and then were kept as controls or treated with 80 μM DAPT for 48 h.